BlueWillow’s intranasal vaccine platform has successfully demonstrated safety and immunogenicity in humans, and safety and efficacy in primary animal models for several diseases. A phase 1 clinical trial in Anthrax is ongoing with interim safety and immunogenicity data expected in May 2021. Clinical trials for an intranasal Covid-19, HSV-2 and pandemic flu vaccines are planned for the near future.
The company has also demonstrated that its adjuvant technology platform shifts the immune response from inflammatory (Th1) to protective (Th2) for food allergies, representing a potential cure. IND-enabling GMP manufacturing and final animal work is being completed for the lead Peanut Allergy program with clinical trials planned for the near future.